This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)”.
The final version of the assessment was published in January 2018. Below is the documentation provided by the Joint Assessment authoring team:
PTJA03 Alectinib Final Assessment Report
Input from external expert and manufacturer on the 2nd draft assessment Alecensa PTJA03 (FINAL)